Journal of Psoriasis and Psoriatic Arthritis最新文献_第8页

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review. 依那西普对银屑病患者剂量调整的更正:回顾性图表回顾

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195871

引用次数: 0

Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update. Brodalumab治疗难治性银屑病的勘误表：病例报告和安全性更新

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-09-02 DOI: 10.1177/24755303231195864

引用次数: 0

Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report. 固定组合0.01%丙酸盐倍他索和0.045%塔扎罗汀洗剂治疗掌跖脓疱病勘误表：一例报告

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231196711

引用次数: 0

Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. Deucravacitinib:一种治疗中重度牛皮癣的新型TYK2抑制剂

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-09-05 DOI: 10.1177/24755303231201336

Paige Kingston, Andrew Blauvelt, Bruce Strober, April W Armstrong

{"title":"Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.","authors":"Paige Kingston, Andrew Blauvelt, Bruce Strober, April W Armstrong","doi":"10.1177/24755303231201336","DOIUrl":"10.1177/24755303231201336","url":null,"abstract":"Background: Deucravacitinib is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of adults with moderate-to-severe plaque psoriasis.Objective: To discuss the mechanism of action, efficacy, safety, and real-world applications of deucravacitinib for the treatment of psoriasis.Methods: Literature on the mechanism of action of deucravacitinib is reviewed. The pivotal clinical studies and long-term extension studies for deucravacitinib are also examined.Results: Deucravacitinib is a novel oral TYK2 inhibitor that binds to the regulatory domain of TYK2, a Janus kinase. By inhibiting TYK2, deucravacitinib interferes with signaling of IL-23, IL-12, and type I interferons, cytokines believed to play important roles in psoriasis pathogenesis. Nearly 60% of patients achieve PASI 75 at 16 weeks of treatment; efficacy improves over 24 weeks and is maintained through 2 years of continuous treatment. In a head-to-head comparison, deucravacitinib efficacy was superior to apremilast, an older yet commonly used oral PDE4 inhibitor approved for the treatment of psoriasis. Of note, patients with moderate-to-severe plaque psoriasis with concomitant involvement of the scalp, nails, and/or palms/soles demonstrated good improvement in these high impact areas. Deucravacitinib has an acceptable safety profile and is generally well-tolerated. Small increases in reactivation of herpesvirus infections, including herpes simplex outbreaks, have been reported. Tuberculosis evaluation, but no other blood tests, is recommended prior to initiation of deucravacitinib. Monitoring of triglyceride levels should be conducted for high-risk patients according to local guidelines.Conclusion: Deucravacitinib is an effective, safe, and well-tolerated novel oral medication for adults with moderate-to-severe plaque psoriasis.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"156-165"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42868235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab. 英夫利昔单抗和乌斯特金单抗联合生物治疗顽固性银屑病缓解的勘误表

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195884

引用次数: 0

Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings. 银屑病和银屑病关节炎临床多中心促进网络联盟（PPAACMAN）2021年会论文集

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-09 DOI: 10.1177/24755303231195967

Carly Grant, Lourdes Perez-Chada, Rebecca H Haberman, Daniel Webster, Oliver FitzGerald, Christopher Ritchlin, Vinod Chandran, Cheryl F Rosen, Brittany Weber, Michael Garshick, Lihi Eder, Soumya M Reddy, Alexis Ogdie, Jose U Scher, Joseph F Merola

{"title":"Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings.","authors":"Carly Grant, Lourdes Perez-Chada, Rebecca H Haberman, Daniel Webster, Oliver FitzGerald, Christopher Ritchlin, Vinod Chandran, Cheryl F Rosen, Brittany Weber, Michael Garshick, Lihi Eder, Soumya M Reddy, Alexis Ogdie, Jose U Scher, Joseph F Merola","doi":"10.1177/24755303231195967","DOIUrl":"10.1177/24755303231195967","url":null,"abstract":"The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives. During the opening session of the meeting, presenters provided an update of several research projects dedicated to predicting and preventing psoriatic arthritis (PsA) such as the Psorcast, PAMPA, HIPPOCRATES, and the ELLIPSS studies. The second session centered around novel approaches to deliver multidisciplinary care in psoriatic disease. PPACMAN leadership introduced its wellness program and invited speakers to discuss new advances in cardiovascular disease, sleep disturbance, mental health problems, and dietary interventions in psoriatic disease. The final session of the meeting focused on how to improve patient engagement in their disease and care.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"179-183"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43463336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis. 更正一例Brodalumab治疗银屑病继发Grover病

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195863

引用次数: 0

Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities. 伴有代谢合并症的银屑病患者生物停药比例的勘误表

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195867

引用次数: 0

A Systematic Review of Follicular Psoriasis: A Unique but Under-Recognized Entity. 毛囊性银屑病的系统评价：一种独特但未被充分认识的实体

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-24 DOI: 10.1177/24755303231196567

Kelli Jablon, Jonathan D Ho, Hye Jin Chung

{"title":"A Systematic Review of Follicular Psoriasis: A Unique but Under-Recognized Entity.","authors":"Kelli Jablon, Jonathan D Ho, Hye Jin Chung","doi":"10.1177/24755303231196567","DOIUrl":"10.1177/24755303231196567","url":null,"abstract":"Background: Follicular psoriasis (FP) is a rare and under-recognized subtype of psoriasis that affects hair follicles and can be frequently misdiagnosed due to its unique presentation.Objective: We aimed to analyze the frequently reported clinical, histological, and dermatoscopic features of FP, as well as their treatment options.Methods: We conducted a systematic review of the PubMed/MEDLINE database using the search terms \"follicular\" and \"psoriasis.\" Fourteen studies were included yielding information on 44 patients (27 adults [61.4%] and 17 children [38.6%]).Results: Adult FP showed a female predominance (M:F = 1:2.7), frequent involvement of lower extremities (81.5%), association with metabolic syndrome including diabetes mellitus (22.2%), and a predilection for skin of color (SOC:White = 8:1). On the contrary, juvenile FP revealed male predominance (M:F = 1:0.6), frequent involvement of the trunk (41.2%), and exclusive involvement in skin of color (SOC:White = 11:0). In addition to its unique presentation, FP tends to be misdiagnosed due to its low incidence of concomitant psoriasis (31.8%), and rare personal (18.2%) or family history (6.8%) of psoriasis. Reported histopathological features include keratotic plugging, follicular parakeratosis with or without neutrophils, psoriasiform acanthosis, hypogranulosis, and neutrophilic infiltration of follicular epithelium. Dermatoscopic findings include folliculocentric lesions with normal appearing terminal hairs, perifollicular white scale, and various vascular structures.Conclusion: Once correctly diagnosed, patients with FP showed improvement or resolution of symptoms with various combinations of topical and systemic therapies. Understanding the demographic features and clinical presentations of FP can help address under-recognition of this clinical variant of psoriasis.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"141-147"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46660247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring. 银屑病指甲变化更正：甲癣镜检查与NAPSI评分的相关性

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195872

引用次数: 0